{
 "Schedule of ratings\u2014respiratory system.": {
  "6502\u2003Septum, nasal, deviation of:": {},
  "Traumatic only,": {
   "With 50-percent obstruction of the nasal passage on both sides or complete obstruction on one side": 10
  },
  "6504\u2003Nose, loss of part of, or scars:": {
   "Exposing both nasal passages": 30,
   "Loss of part of one ala, or other obvious disfigurement": 10
  },
  "6510\u2003Sinusitis, pansinusitis, chronic.": {},
  "6511\u2003Sinusitis, ethmoid, chronic.": {},
  "6512\u2003Sinusitis, frontal, chronic.": {},
  "6513\u2003Sinusitis, maxillary, chronic.": {},
  "6514\u2003Sinusitis, sphenoid, chronic.": {},
  "General Rating Formula for Sinusitis (DC's 6510 through 6514):": {
   "Following radical surgery with chronic osteomyelitis, or; near constant sinusitis characterized by headaches, pain and tenderness of affected sinus, and purulent discharge or crusting after repeated surgeries": 50,
   "Three or more incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; more than six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting": 30,
   "One or two incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting": 10,
   "Detected by X-ray only": 0
  },
  "6515\u2003Laryngitis, tuberculous, active or inactive.": {},
  "Rate under \u00a7\u00a7\u20094.88c or 4.89, whichever is appropriate.": {},
  "6516\u2003Laryngitis, chronic:": {
   "Hoarseness, with thickening or nodules of cords, polyps, submucous infiltration, or pre-malignant changes on biopsy": 30,
   "Hoarseness, with inflammation of cords or mucous membrane": 10
  },
  "Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx (DC 6520).": {},
  "6519\u2003Aphonia, complete organic:": {
   "Constant inability to speak above a whisper": 60
  },
  "6520\u2003Larynx, stenosis of, including residuals of laryngeal trauma (unilateral or bilateral):": {
   "Forced expiratory volume in one second (FEV-1) less than 40 percent of predicted value, with Flow-Volume Loop compatible with upper airway obstruction, or; permanent tracheostomy": 100,
   "FEV-1 of 40- to 55-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction": 60,
   "FEV-1 of 56- to 70-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction": 30,
   "FEV-1 of 71- to 80-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction": 10
  },
  "6521\u2003Pharynx, injuries to:": {
   "Stricture or obstruction of pharynx or nasopharynx, or; absence of soft palate secondary to trauma, chemical burn, or granulomatous disease, or; paralysis of soft palate with swallowing difficulty (nasal regurgitation) and speech impairment": 50
  },
  "6522\u2003Allergic or vasomotor rhinitis:": {
   "With polyps": 30,
   "Without polyps, but with greater than 50-percent obstruction of nasal passage on both sides or complete obstruction on one side": 10
  },
  "6523\u2003Bacterial rhinitis:": {
   "Rhinoscleroma": 50,
   "With permanent hypertrophy of turbinates and with greater than 50-percent obstruction of nasal passage on both sides or complete obstruction on one side": 10
  },
  "6524\u2003Granulomatous rhinitis:": {
   "Wegener's granulomatosis, lethal midline granuloma": 100,
   "Other types of granulomatous infection": 20
  },
  "6600\u2003Bronchitis, chronic:": {
   "FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy": 100,
   "FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)": 60,
   "FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted": 30,
   "FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted": 10
  },
  "6601\u2003Bronchiectasis:": {
   "With incapacitating episodes of infection of at least six weeks total duration per year": 100,
   "With incapacitating episodes of infection of four to six weeks total duration per year, or; near constant findings of cough with purulent sputum associated with anorexia, weight loss, and frank hemoptysis and requiring antibiotic usage almost continuously": 60,
   "With incapacitating episodes of infection of two to four weeks total duration per year, or; daily productive cough with sputum that is at times purulent or blood-tinged and that requires prolonged (lasting four to six weeks) antibiotic usage more than twice a year": 30,
   "Intermittent productive cough with acute infection requiring a course of antibiotics at least twice a year": 10
  },
  "Or rate according to pulmonary impairment as for chronic bronchitis (DC 6600).\n                  ": {},
  "6602\u2003Asthma, bronchial:": {
   "FEV-1 less than 40-percent predicted, or; FEV-1/FVC less than 40 percent, or; more than one attack per week with episodes of respiratory failure, or; requires daily use of systemic (oral or parenteral) high dose corticosteroids or immuno-suppressive medications": 100,
   "FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; at least monthly visits to a physician for required care of exacerbations, or; intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids": 60,
   "FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; daily inhalational or oral bronchodilator therapy, or; inhalational anti-inflammatory medication": 30,
   "FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; intermittent inhalational or oral bronchodilator therapy": 10
  },
  "6603\u2003Emphysema, pulmonary:": {
   "FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy.": 100,
   "FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)": 60,
   "FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted": 30,
   "FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted": 10
  },
  "6604\u2003Chronic obstructive pulmonary disease:": {
   "FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy.": 100,
   "FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)": 60,
   "FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted": 30,
   "FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted": 10,
   "6701\u2003Tuberculosis, pulmonary, chronic, far advanced, active": 100,
   "6702\u2003Tuberculosis, pulmonary, chronic, moderately advanced, active": 100,
   "6703\u2003Tuberculosis, pulmonary, chronic, minimal, active": 100,
   "6704\u2003Tuberculosis, pulmonary, chronic, active, advancement unspecified": 100
  },
  "6721\u2003Tuberculosis, pulmonary, chronic, far advanced, inactive": {},
  "6722\u2003Tuberculosis, pulmonary, chronic, moderately advanced, inactive": {},
  "6723\u2003Tuberculosis, pulmonary, chronic, minimal, inactive": {},
  "6724\u2003Tuberculosis, pulmonary, chronic, inactive, advancement unspecified": {
   "General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following active tuberculosis, which was clinically identified during service or subsequently": 100,
   "Thereafter for four years, or in any event, to six years after date of inactivity": 50,
   "Thereafter, for five years, or to eleven years after date of inactivity": 30,
   "Following far advanced lesions diagnosed at any time while the disease process was active, minimum": 30,
   "Following moderately advanced lesions, provided there is continued disability, emphysema, dyspnea on exertion, impairment of health, etc": 20,
   "Otherwise": 0,
   "6730\u2003Tuberculosis, pulmonary, chronic, active": 100
  },
  "(a) Associated with active tuberculosis involving other than the respiratory system.": {},
  "(b) With severe associated symptoms or with extensive cavity formation.": {},
  "(c) Reactivated cases, generally.": {},
  "(d) With advancement of lesions on successive examinations or while under treatment.": {},
  "(e) Without retrogression of lesions or other evidence of material improvement at the end of six months hospitalization or without change of diagnosis from \u201cactive\u201d at the end of 12 months hospitalization. Material improvement means lessening or absence of clinical symptoms, and X-ray findings of a stationary or retrogressive lesion.\n                  ": {},
  "6731\u2003Tuberculosis, pulmonary, chronic, inactive:": {},
  "Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as removal of ribs under DC 5297.\n                  ": {},
  "6732\u2003Pleurisy, tuberculous, active or inactive:": {},
  "6817\u2003Pulmonary Vascular Disease:": {
   "Primary pulmonary hypertension, or; chronic pulmonary thromboembolism with evidence of pulmonary hypertension, right ventricular hypertrophy, or cor pulmonale, or; pulmonary hypertension secondary to other obstructive disease of pulmonary arteries or veins with evidence of right ventricular hypertrophy or cor pulmonale": 100,
   "Chronic pulmonary thromboembolism requiring anticoagulant therapy, or; following inferior vena cava surgery without evidence of pulmonary hypertension or right ventricular dysfunction": 60,
   "Symptomatic, following resolution of acute pulmonary embolism": 30,
   "Asymptomatic, following resolution of pulmonary thromboembolism": 0,
   "6819\u2003Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths": 100
  },
  "6820\u2003Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy.": {},
  "6822\u2003Actinomycosis.": {},
  "6823\u2003Nocardiosis.": {},
  "6824\u2003Chronic lung abscess.": {},
  "General Rating Formula for Bacterial Infections of the Lung (diagnostic codes 6822 through 6824):": {
   "Active infection with systemic symptoms such as fever, night sweats, weight loss, or hemoptysis": 100
  },
  "Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600).": {},
  "6825\u2003Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis).": {},
  "6826\u2003Desquamative interstitial pneumonitis.": {},
  "6827\u2003Pulmonary alveolar proteinosis.": {},
  "6828\u2003Eosinophilic granuloma of lung.": {},
  "6829\u2003Drug-induced pulmonary pneumonitis and fibrosis.": {},
  "6830\u2003Radiation-induced pulmonary pneumonitis and fibrosis.": {},
  "6831\u2003Hypersensitivity pneumonitis (extrinsic allergic alveolitis).": {},
  "6832\u2003Pneumoconiosis (silicosis, anthracosis, etc.).": {},
  "6833\u2003Asbestosis.": {},
  "General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833):": {
   "Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limitation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy": 100,
   "FVC of 50- to 64-percent predicted, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum exercise capacity of 15 to 20 ml/kg/min oxygen consumption with cardiorespiratory limitation": 60,
   "FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56- to 65-percent predicted": 30,
   "FVC of 75- to 80-percent predicted, or; DLCO (SB) of 66- to 80-percent predicted": 10
  },
  "6834\u2003Histoplasmosis of lung.": {},
  "6835\u2003Coccidioidomycosis.": {},
  "6836\u2003Blastomycosis.": {},
  "6837\u2003Cryptococcosis.": {},
  "6838\u2003Aspergillosis.": {},
  "6839\u2003Mucormycosis.": {},
  "General Rating Formula for Mycotic Lung Disease (diagnostic codes 6834 through 6839):": {
   "Chronic pulmonary mycosis with persistent fever, weight loss, night sweats, or massive hemoptysis": 100,
   "Chronic pulmonary mycosis requiring suppressive therapy with no more than minimal symptoms such as occasional minor hemoptysis or productive cough": 50,
   "Chronic pulmonary mycosis with minimal symptoms such as occasional minor hemoptysis or productive cough": 30,
   "Healed and inactive mycotic lesions, asymptomatic": 0
  },
  "6840\u2003Diaphragm paralysis or paresis.": {},
  "6841\u2003Spinal cord injury with respiratory insufficiency.": {},
  "6842\u2003Kyphoscoliosis, pectus excavatum, pectus carinatum.": {},
  "6843\u2003Traumatic chest wall defect, pneumothorax, hernia, etc.": {},
  "6844\u2003Post-surgical residual (lobectomy, pneumonectomy, etc.).": {},
  "6845\u2003Chronic pleural effusion or fibrosis.": {},
  "General Rating Formula for Restrictive Lung Disease (diagnostic codes 6840 through 6845):": {
   "FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy": 100,
   "FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)": 60,
   "FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted": 30,
   "FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted": 10
  },
  "Or rate primary disorder.\n                  ": {},
  "6846\u2003Sarcoidosis:": {
   "Cor pulmonale, or; cardiac involvement with congestive heart failure, or; progressive pulmonary disease with fever, night sweats, and weight loss despite treatment": 100,
   "Pulmonary involvement requiring systemic high dose (therapeutic) corticosteroids for control": 60,
   "Pulmonary involvement with persistent symptoms requiring chronic low dose (maintenance) or intermittent corticosteroids": 30,
   "Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment": 0
  },
  "Or rate active disease or residuals as chronic bronchitis (DC 6600) and extra-pulmonary involvement under specific body system involved": {},
  "6847\u2003Sleep Apnea Syndromes (Obstructive, Central, Mixed):": {
   "Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy": 100,
   "Requires use of breathing assistance device such as continuous airway pressure (CPAP) machine": 50,
   "Persistent day-time hypersomnolence": 30,
   "Asymptomatic but with documented sleep disorder breathing": 0
  }
 }
}